Search
Filaminast
go.drugbank.com/drugs/DB02660ExperimentalFilaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). As such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Fosigotifator
go.drugbank.com/drugs/DB19409InvestigationalFosigotifator is under investigation in clinical trial NCT05757141 (An Open-label Exploratory Study of ABBV-CLS-7262 Subjects With Vanishing White Matter Disease).
Propentofylline
go.drugbank.com/drugs/DB06479ExperimentalCategories: Compounds used in a research, industrial, or household settingFenpyroximate
go.drugbank.com/drugs/DB16164InvestigationalFenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania
Florzolotau F-18
go.drugbank.com/drugs/DB16297InvestigationalPMPBB3 F-18 is under investigation in clinical trial NCT04305210 (Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18f-florbetapir (AV-45) PET Examination).
Bacteroides thetaiotaomicron
go.drugbank.com/drugs/DB17879InvestigationalBacteroides thetaiotaomicron is a live biotherapeutic. … Developed by 4D Pharma, Thetanix, an oral formulation comprising lyophilized Bacteroides thetaiotaomicron, is being investigated for the treatment of Crohn’s disease.[A259892]
Indole-3-carbinol
go.drugbank.com/drugs/DB12881InvestigationalIndole 3 Carbinol is under investigation in clinical trial NCT00033345 (Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer).
Categories: Compounds used in a research, industrial, or household settingCYNK-101
go.drugbank.com/drugs/DB18637InvestigationalCYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Synonyms: allogeneic human placental hematopoietic stem cell derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP)MIP-1095 I-131
go.drugbank.com/drugs/DB14978InvestigationalMIP-1095 I-131 is under investigation in clinical trial NCT03030885 (Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)).
ALS-08
go.drugbank.com/drugs/DB05705ExperimentalALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.